Pooled CAR-T cells targeting HER2/IL-13Rα2 for glioblastoma (GBM) [108], CD19/CD123 for B-ALL [109], and EGFR/CD133 [110] have been tested in preclinical studies and showed some benefits as well as some disadvantages. This evidence concerns the gene CD19 and glioblastoma.